Mati Therapeutics Inc.

Novartis Ag

Qlt Inc.

Valeant Pharmaceuticals International

Bausch Health Companies Inc.

Hao, Yong

Cadden, Suzanne

Utkhede, Deepank

Yong Hao

Deepank Utkhede

Suzanne Cadden

H Andrew Strong

Valery Rubinchik

Charles Richard Kjellbotn

Troy Albert Reaves, Jr

Mohammad Azab

Charles Richard Kjelbotn

John Miller Koester

Troy Albert Reaves

Andrew Strong

Mohammad Azad

Troy Albert Reaves Jr

A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

Sustained release delivery of active agents to treat glaucoma and ocular hypertension

A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through an upper punctum and into an upper lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a lower punctum and into a lower lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

Drug delivery system and methods of treating open angle glaucoma and ocular hypertension

The use of a combination of photodynamic therapy and an anti-VEGF agent in the treatment of conditions characterized by unwanted choroidal neovasculature is described. These conditions include wet age-related macular degeneration Preferred anti-VEGF agents are antibodies such as bevacizumab or ranibizumab Photosensitizers may be selected from green porphyrins such as BPD-MA (verteporfin) and the photodynamic activation of the photo sensitizer may be accomplished using a reduced fluence rate. The use may further comprises an anti-inflammatory agent such as dexamethasone.

Photodynamic therapy for conditions of the eye

The invention relates to the selection and treatment of subjects afflicted with occult choroidal neovascular lesions, including subjects with age-related macular degeneration, by use of photo dynamic therapy (PDT).

Photodynamic therapy of occult age-related macular degeneration

Growing community of inventors

Vancouver, Canada

Yong Hao